시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 사코페니아 치료 시장 보고서(2025년)
Sarcopenia Treatment Global Market Report 2025
상품코드 : 1825544
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

사코페니아 치료 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.0%로 46억 9,000만 달러로 성장할 전망입니다. 예측기간의 성장은 맞춤의료, 영양 개입, 디지털 건강 플랫폼, 환자 교육 및 강화, 세계 건강 이니셔티브에 기인할 것으로 예상됩니다. 예측기간의 주요 동향으로는 맞춤형 치료, 신규 약물 클래스 출현, 디지털 건강 통합, 공동연구 이니셔티브 및 연구 개발이 포함됩니다.

향후 5년간의 예측 성장률 6.0%는 과거 예측에서 0.1% 소폭 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰로 인해 한국이나 캐나다에서 개발된 장비의 가격이 상승하고 재활 지연과 노인 의료비 상승을 초래하여 미국의 첨단 신경근 전기 자극 장치의 도입을 방해할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 예상됩니다.

영양 실조 증가가 예상되면서 향후 사코페니아 치료 시장의 성장을 견인할 전망입니다. 영양 실조는 개인의 에너지와 영양소 섭취에서 결핍, 과잉, 불균형을 포함하며, 저영양, 과체중, 비만 및 식사와 관련된 비감염성 질환을 모두 포함합니다. 사코페니아 치료는 근육량, 근력 및 전반적인 영양 상태를 강화하는 것을 목표로 하는 영양 요법과 운동과 같은 개입을 통해 노인의 영양 불량과 사코페니아의 병발 상태를 다루는 데 중요한 역할을 합니다. 예를 들어, 세계보건기구(WHO)가 2023년 12월에 발표한 보고서에서는 영양불량이 세계적인 건강상의 중요한 과제로 강조되고 있으며, 2022년에는 4억 6,200만명의 저체중자와 1억 4,900만명의 5세 미만 아동이 발육 저해를 경험한 것으로 나타났습니다. 따라서 영양실조의 급증이 사코페니아 치료 시장 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Sarcopenia treatment encompasses medical interventions and lifestyle strategies tailored to counteract age-related muscle loss, aiming to preserve or enhance skeletal muscle mass and function. The goal of treatment is to mitigate age-related muscle decline, bolster muscle strength, and improve overall physical function and mobility.

The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements, available in forms such as bars, powders, or shakes derived from whey, plant, or meat sources, are utilized for both primary and secondary sarcopenia treatment and can be administered orally, parenterally, or enterally. These supplements are distributed through various channels including hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The sarcopenia treatment market research report is one of a series of new reports from The Business Research Company that provides sarcopenia treatment market statistics, including sarcopenia treatment industry global market size, regional shares, competitors with a sarcopenia treatment market share, detailed sarcopenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. This sarcopenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sarcopenia treatment market size has grown strongly in recent years. It will grow from $3.52 billion in 2024 to $3.72 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle changes, public health initiatives, regulatory approvals.

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine, nutritional interventions, digital health platforms, patient education and empowerment, global health initiatives. Major trends in the forecast period include personalized therapies, emergence of novel drug classes, digital health integration, collaborative research initiatives, research and development.

The forecast of 6.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced neuromuscular electrical stimulation devices by inflating prices of equipment developed in South Korea and Canada, resulting in delayed rehabilitation and higher geriatric care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated increase in malnutrition is poised to drive the growth of the sarcopenia treatment market in the future. Malnutrition encompasses deficiencies, excesses, or imbalances in an individual's intake of energy and nutrients, including both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment plays a crucial role in addressing the concurrent conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, with the aim of enhancing muscle mass, strength, and overall nutritional status. For instance, a report published by the World Health Organization (WHO) in December 2023 highlighted malnutrition as a significant global health challenge, with an estimated 462 million underweight individuals and 149 million children under 5 experiencing stunting in 2022. Consequently, the surge in malnutrition acts as a driving force behind the growth of the sarcopenia treatment market.

Major companies in the sarcopenia treatment market are intensifying their focus on developing multiple advanced clinical studies to enhance treatment options. A clinical study involves a systematic investigation conducted on human subjects to assess the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, disclosed the authorization from the Food and Drug Administration (FDA) to commence the SARA-31 Phase 3 study in sarcopenia. This study aims to assess the efficacy and safety of Sarconeos (BIO101) in treating sarcopenic patients at risk of motor disability. Representing a significant advancement in technological and pharmaceutical treatment modalities, this study offers potential benefits in terms of efficacy and safety for severe sarcopenic patients. Notably, it marks the first-ever Phase 3 study in sarcopenia to receive FDA authorization. The study will involve approximately 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoints will include the evaluation of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

In August 2023, Eli Lilly and Company, a pharmaceutical company based in the US, acquired Versanis Bio in a deal valued at $1.925 billion. Through this acquisition, Lilly's portfolio now includes Versanis' key asset, bimagrumab. This drug is currently in a Phase 2b clinical study, being tested both as a standalone treatment and in combination with semaglutide for adults with overweight or obesity. Versanis Bio is a biotechnology company in the US focused on developing treatments for sarcopenia.

Major companies operating in the sarcopenia treatment market report are Pfizer Inc., F-Hoffmann La-Roche, Merck Sharp & Dohme Corp. (Merck & Co.), AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Eli Lilly and Company, BASF SE, Nestle Health Science, Haleon Group of Companies, Regeneron Pharmaceuticals Inc., DSM, American Way (Amway) Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Ion Labs Inc., Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt. Ltd., Nutrafill

North America was the largest region in the sarcopenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sarcopenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sarcopenia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sarcopenia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sarcopenia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sarcopenia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Sarcopenia Treatment Market Characteristics

3. Sarcopenia Treatment Market Trends And Strategies

4. Sarcopenia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sarcopenia Treatment Growth Analysis And Strategic Analysis Framework

6. Sarcopenia Treatment Market Segmentation

7. Sarcopenia Treatment Market Regional And Country Analysis

8. Asia-Pacific Sarcopenia Treatment Market

9. China Sarcopenia Treatment Market

10. India Sarcopenia Treatment Market

11. Japan Sarcopenia Treatment Market

12. Australia Sarcopenia Treatment Market

13. Indonesia Sarcopenia Treatment Market

14. South Korea Sarcopenia Treatment Market

15. Western Europe Sarcopenia Treatment Market

16. UK Sarcopenia Treatment Market

17. Germany Sarcopenia Treatment Market

18. France Sarcopenia Treatment Market

19. Italy Sarcopenia Treatment Market

20. Spain Sarcopenia Treatment Market

21. Eastern Europe Sarcopenia Treatment Market

22. Russia Sarcopenia Treatment Market

23. North America Sarcopenia Treatment Market

24. USA Sarcopenia Treatment Market

25. Canada Sarcopenia Treatment Market

26. South America Sarcopenia Treatment Market

27. Brazil Sarcopenia Treatment Market

28. Middle East Sarcopenia Treatment Market

29. Africa Sarcopenia Treatment Market

30. Sarcopenia Treatment Market Competitive Landscape And Company Profiles

31. Sarcopenia Treatment Market Other Major And Innovative Companies

32. Global Sarcopenia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sarcopenia Treatment Market

34. Recent Developments In The Sarcopenia Treatment Market

35. Sarcopenia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기